Digital PCR Market Research, 2030
The global digital pcr market was valued at $508.82 million in 2020, and is projected to reach $1,305.30 million by 2030, growing at a CAGR of 8.6% from 2021 to 2030. Digital PCR is an end-point PCR method, which is used for absolute quantification and for analysis of minority sequences against a background of similar majority sequences. Digital PCR (dPCR) enables precise, highly sensitive quantification of nucleic acids. Traditional PCR is an end-point analysis that is semi-quantitative as the amplified product is detected by agarose gel electrophoresis. Real-time PCR (or qPCR) uses fluorescence-based detection to allow the measurement of accumulated amplified product as the reaction progresses. qPCR requires normalization to controls or to a standard curve, allowing only relative quantification. Furthermore, variations in amplification efficiency may affect qPCR results. The digital PCR (dPCR) is mainly classified as droplet digital PCR, chip based digital PCR, and beaming digital PCR.
The growth of the global digital polymerase chain reaction market is majorly driven by the increase in prevalence of different types of cancers such as lung cancer, blood cancer, and brain tumor. Digital PCR test is used for molecular diagnosis of cancer. For instance, as per the Globocan 2020, lung cancer is a second ranked cancer in terms of patient count in Europe with estimated 477,534 newly diagnosed patients. Moreover, advantages of digital PCR over traditional PCR technology such as real time polymerase chain reaction (RT PCR) and quantitative polymerase chain reaction (qPCR) are expected to fuel their adoption in the digital PCR market analysis period. Furthermore, surge in healthcare expenditure of peoples in developing countries and surge in demand for accurate molecular diagnosis of disease drive the digital PCR. market growth.
In addition, surge of COVID-19 pandemic contributes to the growth of digital PCR market share. The advanced digital PCR devices are used as molecular diagnosis tool for detection of COVID-19 infections. For instance, according to World Health Organization (WHO), as of December 2021, around 273 million cases are diagnosed and approximately 5.3 million deaths have been reported globally due to COVID-19. Furthermore, digital PCR devices are used in R&D activities in pharmaceutical sector.
Moreover, advancement in digital PCR technology and rise in number of product launch in the global market are anticipated to contribute toward the growth of the digital PCR industry. For instance, in June 2021, Bio-Rad Laboratories, Inc., one of the global leaders in life science sector, announced the launch of PREvalence ddPCR SARS-CoV-2 wastewater quantification kit for COVID-19 wastewater testing.
Furthermore, the surge in R&D activities for advancement in PCR technology and increase in collaboration agreements between companies for development of digital PCR boosts the growth of digital PCR industry. For instance, in January 2022, Qiagen, a leading developer of diagnostic devices, entered in collaboration with Atila BioSystems and Actome GmbH to provide non-invasive prenatal testing (NIPT) solutions to QIAGEN’s dPCR and licensing & co-marketing agreement. However, high cost of digital PCR devices and reimbursement issues with digital PCR devices impede the growth of this market.
Digital PCR market segmentation
The digital PCR market size is segmented on the basis of technology, product type, application, end user, and region. By technology, the market is categorized into droplet digital PCR (ddPCR), chip based digital PCR, and BEAMing digital PCR. Depending on product type, it is fragmented into digital PCR systems, consumables & reagents, and software & services. On the basis of application, it is segregated into research, clinical diagnostics, and forensic & others.
As per end user, it is differentiated into pharmaceuticals & biotechnology industries, clinical diagnostic laboratories, and universities & other organizations.
By region, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, the UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Arabia, South Africa, and LAMEA).
Depending on technology, the droplet digital PCR (ddPCR) segment dominated the market in 2020, and this trend is expected to continue during the forecast period owing to rise in prevalence of infectious diseases. However, the chip based digital PCR segment is expected to witness considerable growth during the forecast period due to advancement in chip based digital PCR technology.
By Technology
Chip Based Digital Pcr segment held the major share of 8.3% throughout the forecast period.
On the basis of product type, the digital PCR systems segment dominated the market in 2020, and this trend is expected to continue during the forecast period owing to rise in demand for molecular diagnostics in personalized medicine and new product launch. However, the consumables & reagents segment is expected to witness considerable growth during the digital PCR market forecast period due to surge in demand for early diagnosis and increase in number of key players to manufacture consumable and reagents for digital PCR.
By Product Type
Software And Services segment would witness the fastest growth, registering a CAGR of 9.1% during the forecast period.
By application,Depending on end user, the pharmaceuticals & biotechnology industries segment was the major contributor in 2020 and is expected to maintain its lead during the forecast period owing to rise in number of cancer patients. However, the clinical diagnostic laboratories segment is expected to witness considerable growth during the forecast period due to increase in number of clinical research centers and rise in number of clinical trials.
By Application
Forensic And Others segment is projected to be the dominating segment throughout the forecast period.
By region, North America garnered the major share in the digital PCR market in 2020, and is expected to dominate the global market during the forecast period owing to rise in prevalence of cancer, presence of key players for development of digital PCR devices, and well-established infrastructure in the region. However, Asia-Pacific is expected to register the highest CAGR of 10.6% from 2021 to 2030 owing to an increase in the number of hospitals, prevalence of cancer, and high population base.
By Region
North America was holding a dominant position in 2020 and would continue to maintain the lead over the analysis period.
Key Benefits For Stakeholders
- This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the digital pcr market size analysis from 2020 to 2030 to identify the prevailing digital PCR market opportunity.
- The market research is offered along with information related to key drivers, restraints, and opportunities.
- Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
- In-depth analysis of the digital pcr market segmentation assists to determine the prevailing market opportunities.
- Major countries in each region are mapped according to their revenue contribution to the global market.
- Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
- The report includes the analysis of the regional as well as global digital pcr market trends, key players, market segments, application areas, and market growth strategies.
Digital PCR Market Report Highlights
| Aspects | Details |
 Market Size By 2030 | USD 1.3 billion |
 Growth Rate | CAGR of 8.6% |
 Forecast period | 2020 - 2030 |
 Report Pages | 210 |
 By Technology |
|
 By Product Type |
|
 By Application |
|
 By End User |
|
 By Region |
|
 Key Market Players | Bio-Rad Laboratories, Inc., Avance Biosciences, STILLA TECHNOLOGIES, QIAGEN N.V, Precigenome LLC, Sysmex Corporation, Fluidigm Corporation, JN Medsys, LLC, Merck KGaA, Thermo Fisher Scientific, Inc. |
Analyst Review
In accordance with several interviews conducted, top-level CXOs agree that the utilization of dPCR is anticipated to witness a significant rise with technological advancements. In addition, other factors that boost the growth of the market include rise in prevalence of infectious diseases, outbreak of COVID-19 pandemic, and increase in awareness & acceptance of personalized medicines.
The CXOs further added that increase in economic strength of the developing nations, such as Japan, China, India, Indonesia, and Thailand, as well as rise in healthcare expenditure is expected to drive the market growth during the forecast period.
Rapid surge was observed in the adoption of technologically advanced medical devices across developing economies, which is expected to offset the challenging conditions in mature markets, such as North America and Europe. Moreover, North America and Europe are expected to dominate the market during the forecast period, while emerging countries in Asia-Pacific and Latin America are anticipated to offer potential growth opportunities for the market growth.
The total market value of digital PCR market is $508.8 million in 2020.
The forecast period in the report is from 2021 to 2030
The market value of digital PCR Market in 2021 was $620.7 million
The base year for the report is 2020.
Yes, digital PCR companies are profiled in the report
The top companies that hold the market share in digital PCR market are Avance Biosciences, Bio-Rad Laboratories, Inc., Fluidigm Corporation, JN Medsys, Merck KGaA, PreciGenome LLC, Qiagen N.V, Stilla Technologies, Sysmex Corporation and Thermo Fisher Scientific, Inc.
The key trends in the digital PCR market are increase in prevalence of different types of cancers such as lung cancer, blood cancer, and brain tumor.
Loading Table Of Content...
Loading Research Methodology...
